Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 2Urinary Bladder Neoplasms 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Magnetic Resonance Spectroscopy 11Specimen Handling 10Cisplatin 7Radiotherapy 6Paclitaxel 4Cetuximab 4Biopsy 4pembrolizumab 3Platinum 31,2-diaminocyclohexaneplatinum II citrate 3(225)Ac-DOTA-c(RGDyK) 3ipatasertib 2cemiplimab 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Radiation 2Nivolumab 2Immunoglobulin G 2Gemcitabine 2Fluorouracil 2Fluorodeoxyglucose F18 2Disulfides 2Carboplatin 2peposertib 1fluoromisonidazole 1durvalumab 1dl1520 1cabozantinib 1atezolizumab 1advexin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Mouth Neoplasms × advexin × Clear all
NCT00064103 2013-01-23

Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx

National Cancer Institute (NCI)

Phase 1/2 Completed
51 enrolled
Head & Neck

Mouth Neoplasms, Oropharyngeal Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡